Evidence map›Paper›PMID 36497423›Full record

ReviewCancers2022

PET-CT in Clinical Adult Oncology: I. Hematologic Malignancies.

Ahmed Ebada Salem, Harsh R Shah, Matthew F Covington, Bhasker R Koppula, Gabriel C Fine, Richard H Wiggins, John M Hoffman, Kathryn A Morton

Open access · goldAbstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Imaging findings for 2-[Frontiers in medicine · 2025
    Article
  5. Review
  6. Review
  7. Article
  8. Case report:Frontiers in oncology · 2024
    Article
  9. Review
  10. Retrospective Analysis of the Predictive Value ofDiagnostics (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Ahmed Ebada SalemDepartment of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.
Harsh R ShahDepartment of Medicine, Division of Hematology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84132, USA.
Matthew F CovingtonDepartment of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.ORCID 0000-0002-3613-9472
Bhasker R KoppulaDepartment of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.
Gabriel C FineDepartment of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.
Richard H WigginsDepartment of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.ORCID 0000-0003-3984-0982
John M HoffmanDepartment of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.ORCID 0000-0001-8799-8069
Kathryn A MortonDepartment of Radiology and Imaging Sciences, University of Utah, Salt Lake City, UT 84132, USA.ORCID 0000-0001-9861-3478
University of Utah · USIntermountain Healthcare · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PET-CT is an advanced imaging modality with many oncologic applications, including staging, assessment of response to therapy, restaging and evaluation of suspected recurrence. The goal of this 6-part series of review articles is to provide practical information to providers and imaging professionals regarding the best use of PET-CT for the more common adult malignancies. In the first article of this series, hematologic malignancies are addressed. The classification of these malignancies will be outlined, with the disclaimer that the classification of lymphomas is constantly evolving. Critical applications, potential pitfalls, and nuances of PET-CT imaging in hematologic malignancies and imaging features of the major categories of these tumors are addressed. Issues of clinical importance that must be reported by the imaging professionals are outlined. The focus of this article is on [

Indexed as

B-cell lymphomaFDGimagingleukemialymphomamultiple myelomaPETpositron emission tomographyT-cell lymphoma

Identifiers

PMID36497423
PMCPMC9738711
OpenAlexW4311049770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.